Jiang, MD
Chao Jiang, Ellicott City, MD US
Patent application number | Description | Published |
---|---|---|
20160085975 | Constrained Information Transfer - A secure processing facility has a plurality of workstations, with associated computers to provide data to, and/or receive data from, the workstations. The computers are provided with a visual display unit, and display machine-readable data codes on the display. The computers are provided with a scanner to read the machine-readable data codes on the display of another of the computers. The computers have no other connection to receive or transmit machine readable data. A method of operating the facility includes processing a workpiece at a first workstation. A display of the computer of the first workstation displays a data code containing data related to the processing of the workpiece. The scanner of the computer associated with a second workstation scans the data code. The workpiece is transferred from the first workstation to the second workstation. The workpiece is processed at the second workstation. | 03-24-2016 |
Dengrong Jiang, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20150351724 | REAL TIME ULTRASOUND THERMAL DOSE MONITORING SYSTEM FOR TUMOR ABLATION THERAPY - An interventional system with real-time ablation thermal dose monitoring includes an interventional tool, an ultrasound transmitter at least one of attached to or integral with the interventional tool, an ultrasound receiver configured to receive ultrasound signals from the ultrasound transmitter after at least one of transmission through or reflection from a region of tissue while under an ablation procedure and to provide detection signals, and a signal processing system configured to communicate with the ultrasound receiver to receive the detection signals and to calculate, based on the detections signals, a thermal dose delivered to the region of tissue in real time during the ablation procedure. | 12-10-2015 |
Hangyi Jiang, Cockeysville, MD US
Patent application number | Description | Published |
---|---|---|
20090290770 | MRI METHODS USING DIFFUSION TENSOR IMAGING TECHNIQUES AND MRI SYSTEMS EMBODYING SAME - Featured is a method for automatically evaluating acquired MRI data, determining the quality of the acquired images and removing the image data when it is determined that an image is corrupted so the imaged data for the corrupted image is removed from the subsequent tensor fitting. In further embodiments, such determining includes judging the quality of the image data to determine if the image data satisfies a quality threshold criteria and if determined not to be satisfied adjudging the image to be corrupted. Such methods include performing said evaluating, determining and removing in real time and in the case where an image is determined to be corrupted, such methods further includes re-acquiring additional image data corresponding to each of the one or more images removed as being corrupted. Also featured are MRI systems embodying such methods. | 11-26-2009 |
He Jiang, Rockville, MD US
Patent application number | Description | Published |
---|---|---|
20110003735 | PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV INFECTION - This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections. | 01-06-2011 |
20140187476 | PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV INFECTION - This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections. | 07-03-2014 |
Hui Jiang, Clarksburg, MD US
Patent application number | Description | Published |
---|---|---|
20120238842 | INTEGRATED CATALYTIC PROTECTION OF OXIDATION SENSITIVE MATERIALS - An implantable device with in vivo functionality, where the functionality of the device is negatively affected by ROS typically associated with inflammation reaction as well as chronic foreign body response as a result of tissue injury, is at least partially surrounded by a protective material, structure, and/or a coating that prevents damage to the device from any inflammation reactions. The protective material, structure, and/or coating is a biocompatible metal, preferably silver, platinum, palladium, gold, manganese, or alloys or oxides thereof that decomposes reactive oxygen species (ROS), such as hydrogen peroxide, and prevents ROS from oxidizing molecules on the surface of or within the device. The protective material, structure, and/or coating thereby prevents ROS from degrading the in vivo functionality of the implantable device. | 09-20-2012 |
20140088383 | INTEGRATED CATALYTIC PROTECTION OF OXIDATION SENSITIVE MATERIALS - An implantable device with in vivo functionality, where the functionality of the device is negatively affected by ROS typically associated with inflammation reaction as well as chronic foreign body response as a result of tissue injury, is at least partially surrounded by a protective material, structure, and/or a coating that prevents damage to the device from any inflammation reactions. The protective material, structure, and/or coating is a biocompatible metal, preferably silver, platinum, palladium, gold, manganese, or alloys or oxides thereof that decomposes reactive oxygen species (ROS), such as hydrogen peroxide, and prevents ROS from oxidizing molecules on the surface of or within the device. The protective material, structure, and/or coating thereby prevents ROS from degrading the in vivo functionality of the implantable device. | 03-27-2014 |
Jian-Kang Jiang, Columbia, MD US
Patent application number | Description | Published |
---|---|---|
20110195958 | ACTIVATORS OF HUMAN PYRUVATE KINASE - Disclosed are pyruvate kinase M2 activators, which are bis sulfonamide piperazinyl and piperidinyl compounds of Formula (I), 2,4-disubstituted 4H-thieno[3,2-c]pyrrole-2-(substituted benzyl)pyridazin-3(2H)-ones of Formula (II) and 6-(3,4-dimethylphenylaminosulfonyl)-3,4-dihydro-1H-quinolin-2-one of formula (III), wherein L, R | 08-11-2011 |
20120245141 | ACTIVATORS OF HUMAN PYRUVATE KINASE - Disclosed are pyruvate kinase M2 activators, which are, bis sulfonamide piperazinyl compounds of Formula (I) and 2,4-disubstituted 4H-thieno[3,2-b]pyrrole-2-(substituted benzyl)pyridazin-3(2H)ones of Formula (II), wherein L and R | 09-27-2012 |
20140249181 | TROPOLONE COMPOUNDS FOR TREATING OR PREVENTING RETROVIRAL INFECTION - Disclosed are compounds that inhibit RNase H activity of retroviruses, for example, a compound of formula (I) wherein R | 09-04-2014 |
20150050325 | ORGANIC COMPOUNDS - The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to a drug-eluting stent comprising said compounds and methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery. | 02-19-2015 |
20150105395 | ACTIVATORS OF HUMAN PYRUVATE KINASE - Disclosed are pyruvate kinase M2 activators, which are, bis sulfonamide piperazinyl compounds of Formula (I) and 2,4-disubstituted 4H-thieno[3,2-b]pyrrole-2-(substituted benzyl)pyridazin-3(2H)ones of Formula (II), wherein L and R | 04-16-2015 |
Kunqiang Jiang, College Park, MD US
Patent application number | Description | Published |
---|---|---|
20150306587 | Superficially Porous Hybrid Monoliths with Ordered Pores and Methods of Making and using same - The invention provides superficially porous metal oxide or hybrid metal oxide monoliths with ordered pore structures. The superficially porous hybrid silica monoliths of the invention provide several major advantages over existing silica monoliths. When used in chromatography, the superficially porous hybrid silica monoliths of the invention deliver fast separation at very low back pressure and possess superb pH stability and much improved mechanical strength. | 10-29-2015 |
Lingxia Jiang, Boyds, MD US
Patent application number | Description | Published |
---|---|---|
20120088236 | Methods and Systems for Sequential Determination of Genetic Mutations and/or Varients - The present invention relates to methods and systems for genome scanning using high resolution melting analysis for identifying mutations and/or variants in genes of interest. | 04-12-2012 |
Qiong Jiang, Frederick, MD US
Patent application number | Description | Published |
---|---|---|
20140274734 | DNA QUALITY CONTROLS - The present disclosure provides methods, arrays and kits for assessing the quality of genomic DNA samples, especially those obtained from formalin-fixed paraffin-embedded (FFPE) samples. The methods, arrays and kits provided herein use primer pairs specific to regions in the genomes of the organisms from which genomic DNA samples are obtained that have identical or nearly identical copies distributed across multiple chromosomes. | 09-18-2014 |
Rongshong Jiang, Olney, MD US
Patent application number | Description | Published |
---|---|---|
20100227256 | FUEL CELL ASSEMBLY - A passive fuel cell assembly, in which there is neither air pump, nor fuel pump, is comprised of a plurality of bi-cell units. Each bi-cell unit includes a first cell and a second cell, and each cell includes an electrode of a first polarity and an electrode of a second polarity, with an ion permeable membrane disposed therebetween. The bi-cell unit further includes a fuel container which comprises a housing defining a fuel chamber having a first and second open surface. The first and second cells are disposed on opposite sides so that electrodes of each cell having the first polarity are disposed in fluid contact with the fuel chamber. The assembly further includes an oxidizer supply member disposed between adjacent pairs of bi-cell units. The oxidizer supply member includes an oxidizer chamber having four sides to take in air, and having first and second open surfaces. The oxidizer supply member is disposed so that electrodes of the second polarity of adjacent bi-cell units are in fluid contact with the chamber of the oxidizer supply member. The various bi-cell units may be electrically interconnected in mixed series parallel relationship to obtain long operational life. The fuel cell bi-cell assembly may be configured to operate in conjunction with a liquid fuel such as an alcohol, and using air as an oxidizer. | 09-09-2010 |
Rongzhong Jiang, Olnay, MD US
Patent application number | Description | Published |
---|---|---|
20110110836 | DESULFURIZATION APPARATUS AND METHOD - A method and system for desulfurization comprising first and second metal oxides; a walled enclosure having an inlet and an exhaust for the passage of gas to be treated; the first and second metal oxide being combinable with hydrogen sulfide to produce a reaction comprising a sulfide and water; the first metal oxide forming a first layer and the second metal oxide forming a second layer within the walled surroundings; the first and second layers being positioned so the first layer removes the bulk amount of the hydrogen sulfide from the treated gas prior to passage through the second layer, and the second layer removes substantially all of the remaining hydrogen sulfide from the treated gas; the first metal oxide producing a stoichiometrical capacity in excess of 500 mg sulfur/gram; the second metal oxide reacts with the hydrogen sulfide more favorably but has a stoichiometrical capacity which is less than the first reactant; whereby the optimal amount by weight of the first and second metal oxides is achieved by utilizing two to three units by weight of the first metal oxide for every unit of the second metal oxide. | 05-12-2011 |
Rongzhong Jiang, Olney, MD US
Patent application number | Description | Published |
---|---|---|
20080226961 | Electrolyte/membrane assembly for fuel cell, and fuel cell incorporating that assembly - An electrolyte membrane assembly for use in a fuel cell or other electrochemical device includes an ion exchange membrane, a base electrolyte reservoir configured and operable to maintain a volume of a basic electrolyte solution in contact with at least some of the first face of the membrane, and an acid electrolyte reservoir configured and operable to maintain a volume of an acidic electrolyte in contact with at least a portion of the second face of the membrane. The membrane may be a cation exchange membrane or an anion exchange membrane. Also disclosed are fuel cells which incorporate the electrolyte membrane assembly. | 09-18-2008 |
20090263700 | FUEL CELL ASSEMBLY - A fuel cell assembly is comprised of a plurality of stack units. Each stack unit includes a first cell and a second cell, and each cell includes an electrode of a first polarity and an electrode of a second polarity, with an ion permeable membrane disposed therebetween. The stack unit further includes a fuel container which comprises a housing defining a fuel chamber having a first and second open surface. The first and second cells are disposed on opposite sides so that electrodes of each cell having the first polarity are disposed in fluid contact with the fuel chamber. The assembly further includes an oxidizer supply member disposed between adjacent pairs of stack units. The oxidizer supply member includes an oxidizer chamber having first and second open surfaces. The oxidizer supply member is disposed so that electrodes of the second polarity of adjacent stack units are in fluid contact with the chamber of the oxidizer supply member. The various stack units can be electrically interconnected in series, parallel, or mixed series parallel relationship. The fuel cell stack assembly are configured to operate in conjunction with a liquid fuel such as an alcohol, and using air as an oxidizer. | 10-22-2009 |
20100255375 | MOLYBDENUM/AIR BATTERY AND CELL DESIGN - A metal-air battery has an anode in which the electrochemically active material is molybdenum. The molybdenum may be in the form of a bulk body of material or it may comprise a particulate material dispersed with or in another material. In some instances, the molybdenum may comprise a member of an alloy or mixture. Also disclosed is a modular battery system which may include the molybdenum-based anode material. | 10-07-2010 |
20150075997 | POWER-FREE APPARATUS FOR HYDROGEN GENERATION FROM ALCOHOL - An apparatus and method for generating low pressure hydrogen gas from fuel solutions (i.e., alcohols) without the use of an external power source or external heat source. The apparatus comprises (a) a first chamber for fuel storage having an aperture, (b) a second chamber for the temporary storage of hydrogen gas generated having an aperture, (c) a first electrochemical cell (Cell-1) and (d) a second electrochemical cell (Cell-2). Cell-2 is disposed between the first chamber and the second chamber so that its anode is in fluid communication with the first chamber and its cathode is in fluid communication with the second chamber. Cell-1 is disposed on the opposite side of the first chamber from Cell-2 so that the anode therein is in fluid communication with the first chamber, and the cathode therein is in fluid communication with an oxidizing agent. The first chamber is sandwiched between Cell-1 and Cell-2. An air convection window or like device making ambient air available to the apparatus via Cell-1 is positioned on the side of Cell-1 opposite the fuel chamber. In operation, fuel is provided to the first chamber, the anode of Cell-1 is connected to the cathode of Cell-2, and the cathode of Cell-1 is connected to the anode of Cell-2, and hydrogen gas is continuously generated from the hydrogen chamber. The present invention may be used at room temperature. | 03-19-2015 |
20150207163 | METHODS AND APPARATUS OF AN ANODE/CATHODE (A/C) JUNCTION FUEL CELL WITH SOLID ELECTROLYTE - The present invention relates to a fuel cell having an anode; a cathode opposing the anode; a first electrolyte membrane disposed between the anode and the cathode; a second electrolyte membrane disposed between the anode and the cathode; and an A/C junction electrode disposed between the first electrolyte membrane and the second electrolyte membrane, the A/C junction electrode comprising a first gas diffusion layer; a second gas diffusion layer; a current collector disposed between the first gas diffusion layer and the second gas diffusion layer; a first catalyst layer disposed between the first electrolyte membrane and the first gas diffusion layer; and a second catalyst layer disposed between the second electrolyte membrane and the second gas diffusion layer. | 07-23-2015 |
Weiqin Jiang, Rockville, MD US
Patent application number | Description | Published |
---|---|---|
20140249197 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) - The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor. | 09-04-2014 |
Wenlei Jiang, Boyds, MD US
Patent application number | Description | Published |
---|---|---|
20100331387 | LYOPHILIZED PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions that include a poorly water-soluble therapeutic compound, an aqueous solvent, an chelator/antioxidant, a buffer or buffer component, and a bulking agent. The pharmaceutical compositions can be orally ingested or administered parenterally. The pharmaceutical compositions can further be lyophilized to form a pharmaceutically acceptable cake that can be administered orally, e.g., as a solid oral dosage form; or reconstituted and administered parenterally, e.g. as a single i.v. bolus or iv infusion, or administered orally, e.g. as a drink solution. | 12-30-2010 |
Wenlei Jiang, Germantown, MD US
Patent application number | Description | Published |
---|---|---|
20100056500 | Stable Parenteral Formulation - The present invention relates to pharmaceutical formulations of benzodiazepine compounds which are active against Respiratory Syncytial Virus (RSV) suitable for parenteral administration. | 03-04-2010 |
Wen-Lei Jiang, Germantown, MD US
Patent application number | Description | Published |
---|---|---|
20100292291 | FORMULATIONS OF DEACETYLASE INHIBITORS - The present invention provides a stable parenteral formulation of histone deacetylase inhibitors. | 11-18-2010 |
Xuesong Jiang, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20110305768 | QUICK-DISSOLVING ORAL THIN FILM FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS - This invention describes a quick-dissolving thin film strips comprising bioactive components encapsulated within pH-sensitive polymeric microparticles. The microparticles are embedded within the thin film and provide protection to components encapsulated within. The invention further describes methods to incorporate bioactive components encapsulated within pH-sensitive polymeric microparticles into a quick-dissolving thin film strip while maintaining the bioactivity of the contained therapeutic agents during thin film formation and microencapsulation. | 12-15-2011 |
Yimin Jiang, Rockville, MD US
Patent application number | Description | Published |
---|---|---|
20110033016 | METHOD AND APPARATUS FOR PROVIDING CARRIER SYNCHRONIZATION IN DIGITAL BROADCAST AND INTERACTIVE SYSTEMS - An approach is provided for supporting carrier synchronization in a digital broadcast and interactive system. A carrier synchronization module receives one or more signals representing a frame that includes one or more overhead fields (e.g., preamble and optional pilot blocks and one or multiple segments separated by pilot blocks). The module estimates carrier frequency and phase on a segment by segment basis and tracks frequency between segments. Carrier phase of the signal is estimated based upon the overhead field. Estimates carrier phase of random data field are determined based upon the estimated phase values from the overhead fields, and upon both the past and future data signals. Further, the frequency of the signal is estimated based upon the overhead fields and/or the random data field. The above arrangement is particularly suited to a digital satellite broadcast and interactive system. | 02-10-2011 |
Zhi-Gang Jiang, Gaithersburg, MD US
Patent application number | Description | Published |
---|---|---|
20090275587 | METHODS OF TREATING ISCHEMIC RELATED CONDITIONS - The present invention relates to methods of treating ischemia-related conditions by administering to a patient in need of such methods certain thiosemicarbazone compounds. Preferred embodiments of the present invention relates to methods of treating specific ischemia-related conditions, including but not limited to Alzheimer's disease, Parkinson's disease, Coronary artery bypass graft surgery, Global cerebral ischemia due to cardiac arrest, focal cerebral infarction, cerebral hemorrhage, hemorrhage infarction, hypertensive hemorrhage. hemorrhage due to rupture of intracranial vascular abnormalities, subarachnoid hemorrhage due to rupture of intracranial arterial aneurysms, hypertensive encephalopathy, carotid stenosis or occlusion leading to cerebral ischemia, cardiogenic thromboembolism, spinal stroke and spinal cord injury, diseases of cerebral blood vessels: e.g., atherosclerosis, vasculitis, Macular degeneration, myocardial infarction, cardiac ischemia and superaventicular tachyarrhytmia. | 11-05-2009 |
20090286799 | METHODS FOR THE TREATMENT OF BRAIN EDEMA - The present invention is based on the discoveries that PAN-811 (1) reduces infarct volume, suppresses brain edema and decreases mortality associated with ischemia; (2) blocks veratridine-induced swelling and neuronal cell death; (3) chelates free calcium and inhibits MMP-9 activity; and (4) blocks calcium-induced neuronal cell death and suppresses glutamate-induced calcium influx into neuronal cells. More particularly, the present invention relates to methods for treating, ameliorating or preventing vasogenic and/or cytotoxic brain edema, by administering to a subject in need thereof certain thiosemicarbazone compounds or pharmaceutically acceptable salts thereof. An example of such a thiosemicarbazone is 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (PAN-811). | 11-19-2009 |
20140271812 | TREATMENT FOR CHEMOTHERAPY-INDUCED COGNITIVE IMPAIRMENT - The present invention provides methods and compositions for treating chemotherapy-induced cognitive impairment. One embodiment of the present invention is directed to a method of treating chemotherapy-induced cognitive impairment by administering to a patient in need at least one thiosemicarbazone compound. | 09-18-2014 |
20140287021 | TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - The present invention provides methods and compositions for treating chemotherapy induced peripheral neuropathy. One embodiment of the present invention is directed to a method of treating chemotherapy induced peripheral neuropathy by administering to a patient in need at least one thiosemicarbazone compound. | 09-25-2014 |
20140363489 | TREATMENT OF EYE DISEASE - The present invention provides methods and compositions for treating retinal degeneration. One embodiment of the present invention is directed to a method of treating retinal degeneration by administering to a patient in need at least one thiosemicarbazone compound. | 12-11-2014 |
Zhong-Xing Jiang, Dundalk, MD US
Patent application number | Description | Published |
---|---|---|
20090259020 | HIGHLY FLUORINATED BETA-AMINO ACIDS AND METHODS OF MAKING AND USING SAME - Disclosed are compounds having the structure: | 10-15-2009 |
20090264397 | HIGHLY FLUORINATED OILS AND SURFACTANTS AND METHODS OF MAKING AND USING SAME - Disclosed are compounds comprising the structure: | 10-22-2009 |
Zhong-Xing Jiang, Cockeysville, MD US
Patent application number | Description | Published |
---|---|---|
20110217241 | CONJUGATES OF 19F MR IMAGING TRACERS FOR USE IN MULTI-CHROMIC MRI IMAGING - Compositions for producing multi-chromic (“color”) magnetic resonance images (MRI). The compositions for use as MRI imaging agents include a magnetic resonance imaging tracer having a signal emitter, such as a | 09-08-2011 |